Biotech | December 14, 2021
Samsung Biologics expands tie-up with AstraZeneca to include cancer therapy
The company will manufacture a cancer immunotherapy product from 2022
The company will manufacture a cancer immunotherapy product from 2022
The proposed week-long event will comprise specific themes - International engagements, market access and incubation support, funding support to startups etc. and will cover the different areas of the innovation lifecycle
The total cost of the project is estimated at Rs 30 crore
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
The company plans to expand their capacity to meet the needs of pharma and biotech industries
This is the fourth facility from the company to receive this registration
Sputnik M is a new member of the Sputnik vaccines family
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
The hospital is scheduled to open in 2024 with a bed capacity of 225
Subscribe To Our Newsletter & Stay Updated
